TANDEM DIABETES CARE INC (TNDM)
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Tandem Diabetes Care, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 15.83 | 17.32 | 15.45 | 16.91 | 5,879,279 |
| Nov 5, 2026 | 18.93 | 19.57 | 17.63 | 17.99 | 3,026,473 |
| Nov 4, 2026 | 17.83 | 19.29 | 17.83 | 19.05 | 3,714,651 |
| Nov 3, 2026 | 18.67 | 18.67 | 17.61 | 17.65 | 2,567,395 |
| Nov 2, 2026 | 19.34 | 19.59 | 18.42 | 18.67 | 2,901,121 |
| Oct 30, 2026 | 19.42 | 19.59 | 18.71 | 19.11 | 1,874,210 |
| Oct 29, 2026 | 19.71 | 20.25 | 19.46 | 19.79 | 3,357,365 |
| Oct 28, 2026 | 18.93 | 19.71 | 18.75 | 19.68 | 2,137,736 |
| Oct 27, 2026 | 18.73 | 19.25 | 18.18 | 19.22 | 2,059,589 |
| Oct 26, 2026 | 17.42 | 18.98 | 17.21 | 18.90 | 4,488,328 |
| Oct 23, 2026 | 17.06 | 17.56 | 16.89 | 17.43 | 1,820,162 |
| Oct 22, 2026 | 16.47 | 17.20 | 16.24 | 17.15 | 1,871,157 |
| Oct 21, 2026 | 16.60 | 16.95 | 16.12 | 16.35 | 1,532,414 |
| Oct 20, 2026 | 16.47 | 16.86 | 16.37 | 16.52 | 1,587,039 |
| Oct 19, 2026 | 16.23 | 16.52 | 16.00 | 16.38 | 1,272,448 |
| Oct 16, 2026 | 16.61 | 17.25 | 16.14 | 16.24 | 1,634,343 |
| Oct 15, 2026 | 16.01 | 16.55 | 15.61 | 16.52 | 4,590,450 |
| Oct 14, 2026 | 16.64 | 16.70 | 15.86 | 16.01 | 2,221,716 |
| Oct 13, 2026 | 16.23 | 16.80 | 15.71 | 16.65 | 1,708,696 |
| Oct 12, 2026 | 16.11 | 16.91 | 15.86 | 16.45 | 1,579,728 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Option Exercise | 1.7K | $32.3K | Oct 27, 2026 | |
| Director | Sale | 1.7K | $32.6K | Oct 27, 2026 | |
| Director | Option Exercise | 1.7K | -- | Oct 27, 2026 | |
| EVP & Chief Operating Officer | Automatic Sell | 1.9K | $31.8K | Oct 15, 2026 | |
| EVP & Chief Operating Officer | Option Exercise | 3.6K | -- | Oct 15, 2026 | |
| EVP & Chief Operating Officer | Option Exercise | 3.6K | -- | Oct 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 11.6M | 16.6% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Apr 2025 | 10.1M | 14.5% | 13G |
Sessa Capital IM, L.P. | 5.1M | 7.3% | 13F |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3M | 6.2% | 13F |
First Light Asset Management, LLC | 3.4M | 4.8% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | 4.4% | 13F |
STATE STREET CORP | 2.9M | 4.1% | 13F |
GW&K Investment Management, LLC | 2.6M | 3.7% | 13F |
JENNISON ASSOCIATES LLC | 2.3M | 3.3% | 13F |
Paradice Investment Management LLC | 2.0M | 2.9% | 13F |
Insiders
- TWOMEY CHRISTOPHER JDirector
- Kyrillos Jean-ClaudeEVP & Chief Operating Officer
- Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
- Hansen Shannon MarieEVP & Chief Legal Officer
- Sheridan John FPRESIDENT & CEO
- Morrison SusanEVP & Chief Admin. Officer
- Carpenter RickEVP & Chief Technology Officer
- Gasser Elizabeth AnneEVP, Chief Strategy Officer
- Howell Peyton RDirector
- Allen Dick
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally.
The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software.
In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin.
It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories.
The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
13F filers report 78.86M shares, more than the 69.79M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.
30d Avg
2.59M
60d Avg
2.47M
90d Avg
2.13M